Jazz Pharmaceuticals plc (JAZZ) Revenue by Segment
Jazz Pharmaceuticals revenue by segment at a glance
In Q2 fiscal 2026 (the quarter ended June 30, 2026), Jazz Pharmaceuticals's largest product or service was Xywav, with $471.20 million or 39% of revenue, up 13.5% from a year earlier. Next: Epilepsy (24%), Zepzelca (9%) and Rylaze/Enrylaze (8%).
By region, United States brought in 89%, Europe brought in 8% and Other Countries brought in 3% of revenue in Q2 fiscal 2026.
The fastest-growing product or service from a year earlier was Zepzelca (+42.0%).
From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q3 fiscal 2017.
Jazz Pharmaceuticals plc
Revenue breakdown
Fiscal quarters, from company filings
Jazz Pharmaceuticals revenue by product or service, last 4 quarters
| Product or service | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Xywav | $471.2M | $408.2M | $431.4M | $415.3M | 39% |
| Epilepsy | $292.1M | $249.8M | – | $251.7M | 24% |
| Zepzelca | $105.8M | $101.0M | $79.3M | $74.5M | 9% |
| Rylaze/Enrylaze | $99.5M | $103.7M | $99.9M | $100.7M | 8% |
| Defitelio/Defibrotide | $62.0M | $47.4M | $51.8M | $48.1M | 5% |
| Modeyso | $48.2M | $41.4M | $11.0M | $500,000 | 4% |
| High Sodium AG Oxybate Product Royalty Revenue | $42.2M | $36.3M | $52.9M | $54.1M | 3% |
| Vyxeos | $31.4M | $26.6M | $37.6M | $44.9M | 3% |
| Xyrem | $30.5M | $31.2M | $35.7M | $35.4M | 3% |
| Ziihera | $15.4M | $13.3M | $8.3M | $6.0M | 1% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Jazz Pharmaceuticals revenue by region, last 4 quarters
| Region | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| United States | $1.1B | $959.8M | $1.0B | $936.3M | 89% |
| Europe | $97.4M | $92.4M | $86.4M | $82.7M | 8% |
| Other Countries | $33.0M | $16.7M | $19.2M | $26.7M | 3% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Questions and answers
Which product or service makes the most money for Jazz Pharmaceuticals?
Xywav: $471.20 million, or 39% of revenue, in Q2 fiscal 2026.
What are Jazz Pharmaceuticals's main products and services?
By revenue in Q2 fiscal 2026: Xywav (39%), Epilepsy (24%), Zepzelca (9%) and Rylaze/Enrylaze (8%).
Where does Jazz Pharmaceuticals make its money?
By region in Q2 fiscal 2026: United States (89%), Europe (8%) and Other Countries (3%).
